Shuttering of U.S. stores of the debt-laden retailer Toys “R” Us often raised questions about the uncertain future of its Canadian unit that has been profitable for years. However, it appears that the toy retailer will continue its operations in Canada as it is seeking an approval from the court to sell its Canadian operations to an investment firm headquartered in Toronto.
Toys R Us apparently withdrew the auction of its Canadian business — that generates annual revenues of over $1 billion — and is considering the sale of the unit to Fairfax. Toys R Us is currently awaiting an approval for the sale from the bankruptcy court.
Billionaire Prem Watsa’s investment firm has offered $300 million for the Canadian unit. This bid by Fairfax puts an end to the apprehensions looming over the Canadian unit. Post the agreement, Fairfax plans to run the Canadian unit of the troubled retailer under the existing name. This offer by Fairfax, which is known for investing in undervalued assets, sets the platform for other bidders to join in.
Prior to Fairfax, a formal bid was proposed by toymaker Isaac Larian. Currently, the chief executive of MGA Entertainment, Larian has shown interest in acquiring the 200 plus U.S. stores of Toys R US, which the latter declined for being valued too low. He had even offered $215 million to buy the Canadian arm — that stayed functional despite the closure of stores in the U.S. and the U.K. — but got a blow when Fairfax easily topped his offer.
Toys R Us apparently withdrew the auction of its Canadian business — that generates annual revenues of over $1 billion — and is considering the sale of the unit to Fairfax
Larian, who had initiated a crowdfunding campaign to raise funds to support his buyout bid, finds Toys R Us Canadian operations as a good business. He still has the chance to sweeten his bid. In such a scenario, Fairfax can either increase its bid or can choose to abandon the bidding process. If in case of Toys R Us fails to strike a deal with Fairfax, it is liable to offer Fairfax a break fee of about 3%.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on